SCHEMBL3482827

SCHEMBL3482827

CCOCCNC(=O)c1ccc(-c2ccn3ncc(C=O)c3n2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ESR1 P03372 1/20 0.38
POLB P06746 1/20 0.38
JMJD7 P0C870 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
STAT3 P40763 1/20 0.38
STAT1 P42224 1/20 0.38
RAB9A P51151 1/20 0.38
AKT3 Q9Y243 6/20 0.37
CAMK2D Q13557 6/20 0.37
KCNH2 Q12809 1/20 0.36
KMT2A Q03164 2/20 0.36
RXFP1 Q9HBX9 2/20 0.35
TP53 P04637 1/20 0.35
PIK3CA P42336 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12979532 0.85 SMN1; SMN2 (0.34) NPC1SMN1; SMN2KDM4EESR1POLB
SCHEMBL12979694 0.85 SMN1; SMN2 (0.34) NPC1SMN1; SMN2KDM4EESR1POLB
SCHEMBL14679096 0.84 NPC1 (0.34) NPC1SMN1; SMN2KDM4EESR1POLB
SCHEMBL12979020 0.82 CAMK2D (0.39) AKT3CAMK2DKCNH2
SCHEMBL860779 0.80 DYRK1A (0.40) AKT3CAMK2D
SCHEMBL859969 0.78 KDM4E (0.39) NPC1SMN1; SMN2KDM4EPOLBGAA
SCHEMBL13021548 0.76 PIK3CA (0.33) MAPTPIK3CAPIK3CG
SCHEMBL3483033 0.68 PRF1 (0.42) AKT3CAMK2DKCNH2
SCHEMBL3483036 0.68 PRF1 (0.42) AKT3CAMK2DKCNH2
SCHEMBL12979332 0.68 PRF1 (0.42) AKT3CAMK2DKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 NPC1 3761/4885SMN1; SMN2 4465/4885KDM4E 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.